Acute Leukæmia in Myeloma

Hove, W. Van; Hamers, J; Demeulenaere, L

doi:10.1016/s0140-6736(73)92395-7

Cited by 9 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient was among those reported by Rosner and G runw ald [1], They were usually among the longest survivors, and in most cases, MM appeared to be in remission when acute leukemia was discovered [1][2][3][4][5][6], The mean duration from the diagnosis of MM to the development of acute leukemia in the reported series ranged from 39 months in the Mayo series [3] to 63 months in the group treat ed by melphalan alone and 56 months with the group treated by melphalan plus irradiation in a series of patients reported by acute leukemia group B (ALGB) [1]. The mean latent period in our four patients was 72 months and similar fin dings of a relatively longer interval have also been experienced by others [2,4,5], This complication has been generally attributed to the oncogenic potential of alkylating agents and irradiation. However, in 13 instances [10][11][12][13][14], the two diseases occurred simultaneously, without previous chemotherapy.…”

Section: Discussionmentioning

confidence: 96%

Second Malignancies in Patients with Multiple Myeloma

Law¹,

Blom²

1977

Oncology

View full text Add to dashboard Cite

Seven patients with multiple myeloma who developed a second neoplasm are presented. There were four patients with acute leukemia and three patients with non-hematologic neoplasms. The patients with acute leukemia were among the longest survivors (median duration ≈ 72 months) and the response to anti-leukemic therapy in these patients was generally poor. Of the three patients with non-hematologic neoplasms, one patient was observed with simultaneous renal cell carcinoma and the other two patients developed adenocarcinoma of the colon and lung subsequently. In addition, two patients with mammary carcinoma who subsequently developed multiple myeloma were included. Literature was reviewed and the possibility that multiple myeloma itself might be a risk factor for the development of other malignancies was discussed.

show abstract

Section: Discussionmentioning

confidence: 96%

Second Malignancies in Patients with Multiple Myeloma

Law¹,

Blom²

1977

Oncology

View full text Add to dashboard Cite

show abstract

Second malignant neoplasms associated with immunosuppressive medications

Penn¹

1976

Cancer

129

View full text Add to dashboard Cite

Previous studies have shown that immunosuppressive therapy permits the growth and spread of inadvertently transplanted malignant cells in man, and, in addition, is associated with a 5 to 6% incidence of de novo cancers in organ homograft recipients who were apparently free of cancer before and at the time of transplantation. In the present report two further groups of patients were studied. There was a 4% incidence of new tumors in 101 organ homograft recipient- who had had pre-existing cancers. The immunosuppressive effects of cancer chemotherapeutic agents may have been responsible for the development of 166 new malignancies in 160 patients who received treatment for 161 neoplasms. This does not contraindicate the use of chemotherapy in patients with advanced or widespread neoplasms, as the occasional development of new malignancies is far outweighed by the many months or years of control of the original tumors.

show abstract

Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy

Preisler

Lyman

1977

American J Hematol

View full text Add to dashboard Cite

The clinical characteristics of 10 patients with acute myelogenous leukemia (AML) which developed subsequently to treatment for another neoplasm are described. This disease appears to differ from "spontaneous" AML in being associated with lesser degrees of leukemic infiltration of the marrow and more frequent chromosomal aberrations. Only one of the nine patients who received chemotherapy attained remission status, and the mean and median survivals from the initiation of chemotherapy were 2.7 months and one month respectively. Nine of the 10 patients died as a result of infection. The refractoriness of this form of AML to chemotherapy was borne out by a review of the literature, which revealed only two remissions in 32 treated patients. The implications for the management of this disease are discussed.

show abstract

Acute Leukæmia in Myeloma

Cited by 9 publications

References 4 publications

Second Malignancies in Patients with Multiple Myeloma

Second Malignancies in Patients with Multiple Myeloma

Second malignant neoplasms associated with immunosuppressive medications

Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy

Contact Info

Product

Resources

About